中美洲胃癌治疗市场，按类型（腺癌、胃肠道间质瘤、类癌瘤、淋巴瘤等）、分期（III 期、II 期、IV 期、I 期等）、治疗（化疗、靶向治疗、免疫检查点抑制剂等）、给药途径（肠外、口服等）、最终用户（医院、专科诊所、研究和学术机构等）、分销渠道（医院药房、零售药房等）划分 - 行业趋势和预测到 2029 年。
中美洲胃癌治疗市场分析和见解
胃癌是世界上第四种最常见的癌症,也是癌症死亡的第二大原因。 胃癌是细胞从胃开始的异常生长. 胃癌,也叫胃癌胃癌,可以影响任何部分的胃. 在世界大部分地区,胃癌形成于胃的主要部位(stomach body). 但在美国,胃癌更容易影响食道与胃相会的地区. 这一地区被称作"胃口".
随着老年病人数的增加,胃肠道肿瘤的发病率增加,这表明了胃癌治疗数量的上升。 因此,估计老年人口的增长是推动市场增长的一个主要因素。
胃癌治疗是支持性的,旨在减少疾病的蔓延。 数据桥市场研究分析认为,在2022年至2029年的预测期间,遗传性胃癌治疗将以7.2%的CAGR增长.
|
报表计量 |
细节 |
|
预测期 |
2022至2029年统计 |
|
基准年 |
2021 |
|
历史年代 |
2020年(2019-2014年可定制). |
|
数量单位 |
收入(百万美元),定价(美元) |
|
覆盖部分 |
按类型(Adenocarcinoma、胃肠胃肿瘤、Carcinoid肿瘤、淋巴瘤等)、阶段(第一阶段、第二阶段、第三阶段、第四阶段等)、治疗(化学疗法、定向治疗、免疫检查点缺勤者等)、行政路线(Oral、家长及其他)、最终用户(医院、专科诊所、研究和学术机构等)、分发渠道(医院药房、零售药店等) |
|
涵盖国家 |
哥斯达黎加、危地马拉、巴拿马、多米尼加共和国和中美洲其他地区 |
|
覆盖的市场玩家 |
Hoffmann-La Roche有限公司、Merck & Co.公司、Pfize公司、Teva制药工业有限公司、AstraZeneca、Bayer AG、Novartis AG、Bristol-Myers Squibb公司、Eli Lily和公司、Laboratorio Variframa SA、七药厂、Janssen Global Services、LLC(Johnson & Johnson Services Inc.的子公司)和Sanofi等 |
胃癌治疗市场动态
司机
- 胃肠道肿瘤发病率增加,淋巴瘤和阿德诺卡西诺玛
胃肠道肿瘤、淋巴瘤和腺癌的发病率增加,通过利用最新技术,对早期发现和诊断的需求不断增加,从而推动了中美洲胃癌治疗市场的增长。
- 酒精消费上升和吸烟激增
混合使用香烟和酒精引起健康问题和严重的公共卫生问题,共同导致胃癌。 每次吸烟者吸入一盏点燃的香烟,产生数十种危险化学品,都会发生化学链反应. 烟雾含有通过口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口口
此外,这些国家的肥胖症高发率预计将推动中美洲胃癌治疗市场的增长。
此外,主要行为者的战略举措增加、医疗技术的进步、最近在胃癌治疗方面的进步、公共和私营组织提高认识的举措增加以及政府供资增加,是扩大胃癌治疗市场的因素。
机会
- 中美洲国家保健支出
此外,提高认识和求诊率的提高以及治疗方面新出现的偿还政策将为市场增长率提供新的机会。
此外,越来越多的药品批准将为2022-2029年预测期的胃癌治疗市场提供有益的机会。 此外,主要角色的伙伴关系和协议将在未来使胃癌治疗市场的增长率升级。
限制/挑战
然而,与其他医疗和干预(如外科干预和放射治疗)和辅助护理(如抗乳道和肝脏生长因素)有关的费用将使总体护理更加难以负担。 即使有保险,许多国家的癌症患者也报告了经济压力,以至于可能降低治疗剂量,部分补药,甚至完全放弃治疗。
这份胃癌治疗市场报告详细介绍了近期新发展,贸易监管,进出口分析,生产分析,价值链优化,市场份额,国内和地方市场主体影响等情况,分析了新兴收入口号,市场监管变化,战略性市场增长分析,市场规模,类别市场增长,应用优势和支配地位,产品审批,产品推出,地域扩张,市场技术创新等方面的机会. 为了获得更多关于胃癌治疗市场的信息 联系数据桥市场研究 一个分析员简报, 我们的团队将帮助你做出知情的市场决定 实现市场增长。
患者流行病学分析
胃癌病是世界第5个最常被诊断出癌症的疾病,也是第7个最流行的疾病.胃癌在男性中更为普遍。 在发达国家,男性诊断出胃癌的可能性是女性的2.2倍。 在发展中国家,这一比例为1.83。 在全世界5个国家,胃癌在所有男性癌症中发病率最高。
大多数胃癌(约90%至95%)为腺癌。 这些癌症由胃最内侧的腺细胞(黏液)发展而来. 胃癌主要影响老年人。 确诊的平均年龄为68岁. 每年每10名诊断出胃癌的人中约有6名是65名或65名以上。 男子患胃癌的终生风险(96分之一左右)高于妇女(152分之一左右)。 但每个人的风险都可能受到许多其他因素的影响
胃癌治疗市场也为您提供了详细的病人分析,预后和治疗的市场分析. 流行率、发生率、死亡率、坚持率是报告中现有的一些数据变量。 对流行病学对市场增长的直接或间接影响分析进行了分析,以便为预测增长时期的市场建立一个更加有力和组合的多变统计模型。
COVID-19之后对胃癌治疗的影响 市场
COVID-19对市场产生了负面影响. 流行病期间的封锁和隔离使疾病管理和药物坚持情况复杂化。 无法利用保健设施进行例行治疗和药物管理将进一步影响市场。 社会孤立增加了压力、绝望和社会支持,所有这些都可能导致在大流行病期间抗惊厥药物的坚持率下降。
最近的发展
- 2021年3月,以发展免疫肿瘤学和定向癌症疗法为主的临床阶段生物技术公司"安根与五原疗法"(Amgen and Five Prime Theathemeutics)宣布了一项协议,根据该协议,安根将获得五原疗法. 采购还将包括Bemarituzumab,A阶段3胃癌方案
中美洲胃癌治疗 市场范围
中美洲胃癌治疗市场分为六个值得注意的部分,分别是类型、阶段、治疗、管理路线、最终用户和分销渠道。 这些部门之间的增长将有助于你分析这些行业中增长不足的部分,并为用户提供宝贵的市场概况和市场见解,以便作出战略决定,确定核心市场应用。
类型
- 亚多诺卡西诺马
- 淋巴瘤
- 胃肠胃瘤
- 肿瘤
- 其他人员
根据类型,市场被分化为腺癌,淋巴瘤,胃肠分泌的分泌瘤,鲤鱼瘤等.
阶段
- 第一阶段
- 第二阶段
- 第三阶段
- 第四阶段
- 其他人员
以阶段为基础,将市场分为一,二,三,四等阶段.
治疗
- 化学疗法
- 定点治疗
- Immune 检查站
- 其他人员
以治疗为基础,将市场分为化疗,定点疗法,免疫疗法等.
行政路线
- 口头
- 家长
根据管理路线,市场分为口述和亲述两种.
结束用户
- 医院
- 专科诊所
- 研究和学术机构
- 其他人员
在最终用户的基础上,中美洲胃癌治疗市场分为医院、专科诊所、研究和学术机构等。
分发频道
- 零售药店
- 医院药房
- 其他人员
中美洲胃癌治疗市场也根据分销渠道分为零售药店、医院药店等。
管道分析
对药物的管道分析包括各种管道疗法,如Zolbetuximab(IMAB362)外加mFOLFOX6、Nivolumab和Ipilimumab、Pembrolizumab(MK-3745)外加Cisplatin、Regorafenib(Stivarga、BAY73-4506)、Lapatinib、NCT03653507、Durvalomab或Placebo和FLOT Chemothery。 Astellas Pharma Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Bayer AG, Novartis AG 参与开发改进胃癌治疗的潜在药物.
胃癌治疗市场 区域分析/见解
分析胃癌治疗市场,并按国家、类型、阶段、治疗、管理路线、最终用户和分销渠道提供市场规模的见解和趋势。
胃癌治疗市场报告所涵盖的国家是哥斯达黎加、危地马拉、巴拿马、多米尼加共和国和中美洲其他地区。
就市场份额和市场收入而言,哥斯达黎加在胃癌治疗市场中占主导地位,在预测期间将继续发挥主导作用。 这是由于该国主要行为者的存在和完善的保健基础设施。
报告的国家部分还提供了个别市场影响因素和影响市场当前和未来趋势的市场监管变化。 数据点,如新的和替换销售、国家人口统计、疾病流行病学和进出口关税,是用来预测个别国家市场情况的一些主要指针。 此外,在提供国家数据的预测分析的同时,还考虑到全球品牌的存在和可得性及其因来自当地和国内品牌的高度竞争而面临的挑战,以及销售渠道的影响。
竞争性景观和中美洲胃癌治疗市场 共享分析
胃癌治疗市场竞争环境提供了竞争者的详细信息。 详细情况包括公司概况、公司财务、创收、市场潜力、研发投资、新市场举措、全球存在、生产地点和设施、生产能力、公司优势和弱点、产品推出、产品宽度和广度以及应用优势。 上述数据点仅涉及公司对胃癌治疗的重视。
在中美洲胃癌治疗市场上经营的一些主要公司有:F. Hoffmann-La Roche有限公司、Merck & Co. Inc.、Pfize公司、Teva制药工业有限公司、AstraZeneca、Bayer AG、Novartis AG、Bristol-Myers Squibb公司、Eli Lilly and Company、Laboratorio Variframa SA、七药厂、Janssen Global Services、LC(Johnson & Johnson Services Inc.的子公司)和Sanofi等。
研究方法
数据收集和基准年分析使用具有大样本规模的数据收集模块。 利用市场统计和连贯一致的模式分析和估计市场数据。 此外,市场份额分析和主要趋势分析是市场报告的主要成功因素. DBMR研究小组采用的关键研究方法是数据三角化,涉及数据挖掘、数据变量对市场的影响分析以及初级(工业专家)验证。 除此之外,数据模型还包括供应商定位网格、市场时间线分析、市场概况和指南、公司定位网格、公司市场份额分析、计量标准、全球Vs区域和供应商份额分析。 如有进一步调查,请联系分析师。
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 MULTIVARIATE MODELLING
2.8 TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTERS FIVE FORCES
4.3 INNOVATIVE TREATMENT VS CHEMOTHERAPY
4.3.1 TARGETED THERAPIES
4.3.2 CHEMOTHERAPY
4.3.3 CONCLUSION
4.3.4 PRIMARY LINE OF TREATMENT OF GASTRIC CANCER
5 EPIDERMOLOGY
6 PIPELINE ANALYSIS FOR CHILE GASTRIC CANCER TREATMENT MARKET
7 REGULATIONS OF CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET
7.1 COSTA RICA
7.2 GUATEMALA
7.3 PANAMA
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASE IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA, AND ADENOCARCINOMA
8.1.2 RISE IN ALCOHOL CONSUMPTION AND SURGE IN SMOKING
8.1.3 HIGH INCIDENCE OF OBESITY
8.1.4 RECENT ADVANCEMENT IN GASTRIC CANCER TREATMENT
8.2 RESTRAINTS
8.2.1 HIGH COST OF TESTING AND MEDICATIONS
8.2.2 ADVERSE SIDE-EFFECTS OF GASTRIC CANCER TREATMENT
8.3 OPPORTUNITIES
8.3.1 HEALTHCARE EXPENDITURE IN CENTRAL AMERICAN COUNTRIES
8.3.2 INCREASING DRUG APPROVALS
8.3.3 PARTNERSHIP AND AGREEMENT BY MAJOR PLAYERS
8.3.4 INCREASING SUPPORT OF PRIVATE AND GOVERNMENT AGENCIES FOR TREATMENT
8.4 CHALLENGES
8.4.1 OLD AGE CHALLENGES
8.4.2 ALTERNATIVE GASTRIC CANCER THERAPIES
9 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY TYPE
9.1 OVERVIEW
9.2 ADENOCARCINOMA
9.3 GASTROINTESTINAL STROMAL TUMOR
9.4 CARCINOID TUMOR
9.5 LYMPHOMA
9.6 OTHERS
10 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY STAGES
10.1 OVERVIEW
10.2 STAGE III
10.3 STAGE II
10.4 STAGE IV
10.5 STAGE I
10.6 OTHERS
11 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT
11.1 OVERVIEW
11.2 CHEMOTHERAPY
11.2.1 FLUOROURACIL
11.2.2 OXALIPLATIN
11.2.3 CISPLATIN
11.2.4 DOCETAXEL
11.2.5 PACLITAXEL
11.2.6 IRINOTECAN
11.2.7 CAPECITABINE
11.2.8 CARBOPLATIN
11.2.9 EPIRUBICIN
11.2.10 OTHERS
11.3 TARGETED THERAPY
11.3.1 MONOCLONAL ANTIBODY THERAPY
11.3.1.1 TRASTUZUMAB (HERCEPTIN)
11.3.1.2 RAMUCIRUMAB
11.3.2 MULTIKINASE INHIBITORS
11.3.2.1 SUNITINIB
11.3.2.2 REGORAFENIB
11.4 IMMUNE CHECKPOINT INHIBITORS
11.5 OTHERS
12 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 PARENTERAL
12.2.1 INTRAVENOUS
12.2.2 SUBCUTANEOUS
12.2.3 OTHERS
12.3 ORAL
12.3.1 TABLET
12.3.2 CAPSULE
12.3.3 OTHERS
12.4 OTHERS
13 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 SPECIALITY CLINICS
13.4 RESEARCH & ACADEMIC INSTITUTES
13.5 OTHERS
14 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 OTHERS
15 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY COUNTRY
15.1 CENTRAL AMERICA
15.1.1 COSTA RICA
15.1.2 PANAMA
15.1.3 GUATEMALA
15.1.4 DOMINICAN REPUBLIC
15.1.5 REST OF CENTRAL AMERICA
16 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: CENTRAL AMERICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 MERCK & CO., INC
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENTS
18.1.4.1 PRODUCT APPROVAL
18.1.4.2 EVENTS
18.2 F.HOFFMANN-LA ROCHE AG
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 PRODUCT PORTFOLIO
18.2.4 RECENT DEVELOPMENT
18.2.4.1 AGREEMENT
18.3 ELI LILLY AND COMPANY
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 PRODUCT PORTFOLIO
18.3.4 RECENT DEVELOPMENT
18.3.4.1 APPROVAL
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 PRODUCT PORTFOLIO
18.4.4 RECENT DEVELOPMENT
18.4.4.1 COLLABORATION
18.5 BRISTOL-MYERS SQUIBB COMPANY
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.5.4.1 PRODUCT APPROVAL
18.6 BAYER AG
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENT
18.6.4.1 COLLABORATION
18.7 SEVEN PHARMA
18.7.1 COMPANY SNAPSHOT
18.7.2 PRODUCT PORTFOLIO
18.7.3 RECENT DEVELOPMENT
18.8 JANSSEN GLOBAL SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.)
18.8.1 COMPANY SNAPSHOT
18.8.2 REVENUE ANALYSIS
18.8.3 PRODUCT PORTFOLIO
18.8.4 RECENT DEVELOPMENT
18.9 ASTRAZENECA
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.9.4.1 PRODUCT APPROVAL
18.1 LABORATORIO VARIFARMA SA
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.10.3.1 EXPANSION
18.11 NOVARTIS AG
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENT
18.11.4.1 PRODUCT LAUNCH
18.12 PFIZER INC.
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.12.4.1 MERGER
18.12.4.2 COLLABORATION
18.13 SANOFI
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENT
18.13.4.1 ACQUISITION
19 QUESTIONNAIRE
20 RELATED REPORTS
表格列表
T, BY STAGES, 2020-2029 (USD MILLION)
TABLE 5 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 6 CENTRAL AMERICA CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 7 CENTRAL AMERICA TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 8 CENTRAL AMERICA MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 9 CENTRAL AMERICA MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 10 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 11 CENTRAL AMERICA PARENTERAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 12 CENTRAL AMERICA ORAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 13 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 14 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 15 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 16 COSTA RICA GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 COSTA RICA GASTRIC CANCER TREATMENT MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 18 COSTA RICA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 19 COSTA RICA CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 20 COSTA RICA TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 21 COSTA RICA MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 22 COSTA RICA MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 23 COSTA RICA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 24 COSTA RICA PARENTERAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 25 COSTA RICA ORAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 26 COSTA RICA GASTRIC CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 27 COSTA RICA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 28 PANAMA GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 PANAMA GASTRIC CANCER TREATMENT MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 30 PANAMA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 31 PANAMA CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 32 PANAMA TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 33 PANAMA MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 34 PANAMA MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 35 PANAMA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 36 PANAMA PARENTERAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 37 PANAMA ORAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 38 PANAMA GASTRIC CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 39 PANAMA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 40 GUATEMALA GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 GUATEMALA GASTRIC CANCER TREATMENT MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 42 GUATEMALA GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 43 GUATEMALA CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 44 GUATEMALA TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 45 GUATEMALA MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 46 GUATEMALA MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 47 GUATEMALA GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 48 GUATEMALA PARENTERAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 49 GUATEMALA ORAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 50 GUATEMALA GASTRIC CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 51 GUATEMALA GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 52 DOMINICAN REPUBLIC GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 DOMINICAN REPUBLIC GASTRIC CANCER TREATMENT MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 54 DOMINICAN REPUBLIC GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 55 DOMINICAN REPUBLIC CHEMOTHERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 56 DOMINICAN REPUBLIC TARGETED THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 57 DOMINICAN REPUBLIC MONOCLONAL ANTIBODY THERAPY IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 58 DOMINICAN REPUBLIC MULTIKINASE INHIBITORS IN GASTRIC CANCER TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD MILLION)
TABLE 59 DOMINICAN REPUBLIC GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 60 DOMINICAN REPUBLIC PARENTERAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 61 DOMINICAN REPUBLIC ORAL IN GASTRIC CANCER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 62 DOMINICAN REPUBLIC GASTRIC CANCER TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 63 DOMINICAN REPUBLIC GASTRIC CANCER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 64 REST OF CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: SEGMENTATION
FIGURE 2 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: MULTIVARIATE MODELLING
FIGURE 8 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: END USER OVERAGE GRID
FIGURE 11 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: SEGMENTATION
FIGURE 12 INCREASING IN INCIDENCE OF GASTROINTESTINAL TUMORS, LYMPHOMA AND ADENOCARCINOMA AND HIGH PREVALENCE OF OBESITY ARE EXPECTED TO DRIVE THE CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 ADENOCARCINOMA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET IN 2022 & 2029
FIGURE 14 CONDITIONALLY RECOMMENDED REGIME
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET
FIGURE 16 PER CAPITA EXPENSE AND HEALTHCARE EXPEDITURE (% OF GDP) OF COSTA RICA
FIGURE 17 PER CAPITA EXPENSE AND CURRENT HEALTHCARE EXPEDITURE (% OF GDP) OF GUATEMALA
FIGURE 18 PER CAPITA EXPENSE AND CURRENT HEALTHCARE EXPEDITURE (% OF GDP) OF GUATEMALA
FIGURE 19 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2021
FIGURE 20 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 21 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 22 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TYPE, 2020-2029, LIFELINE CURVE
FIGURE 23 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY STAGES, 2021
FIGURE 24 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY STAGES, 2022-2029 (USD MILLION)
FIGURE 25 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY STAGES, CAGR (2022-2029)
FIGURE 26 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 27 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, 2021
FIGURE 28 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, 2022-2029 (USD MILLION)
FIGURE 29 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, CAGR (2022-2029)
FIGURE 30 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 31 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 32 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 33 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 34 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029, LIFELINE CURVE
FIGURE 35 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY END USER 2021
FIGURE 36 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 37 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY END USER, CAGR (2022-2029)
FIGURE 38 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY END USER, 2020-2029, LIFELINE CURVE
FIGURE 39 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 40 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 41 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 42 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: SNAPSHOT (2021)
FIGURE 44 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY COUNTRY (2021)
FIGURE 45 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY COUNTRY (2022 & 2029)
FIGURE 46 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY COUNTRY (2021 & 2029)
FIGURE 47 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: BY TYPE (2022-2029)
FIGURE 48 CENTRAL AMERICA GASTRIC CANCER TREATMENT MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。
